Latest Market Research News

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

Aland Equity Group reported a sharp revenue decline and an 85% increase in losses for the half-year ending December 2025, while completing a major capital raise and reshuffling its board.

Pureprofile Ltd reported a robust 14.2% increase in revenue and a 21.6% rise in net profit for H1 FY26, driven by international expansion and AI-powered platform growth. The company also announced a strategic acquisition to deepen its market research capabilities.

Pureprofile Limited has agreed to acquire CRNRSTONE, an established Australian qualitative research firm, for $700,000 in cash, enhancing its market research capabilities and expected to be earnings accretive from year one.

Botanix Pharmaceuticals has launched a A$45 million capital raising to support the expansion of its dermatology product Sofdra®, while negotiating to reduce active pharmaceutical ingredient costs by up to 40%. The raising includes a two-tranche placement and a security purchase plan, with options offered to investors.

Breville Group Limited has reported a record half-year revenue of AUD 1.1 billion, overcoming US tariff challenges through strategic manufacturing shifts and robust product innovation. The company’s steady profitability and geographic expansion signal a confident growth trajectory.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Botanix Pharmaceuticals reported a robust 28% increase in net revenue for Sofdra in Q2 FY26, driven by a 24% rise in prescriptions and a growing US sales team. The company maintains a strong cash position while navigating higher operating costs.

Anteris Technologies Global Corp. has launched a $230 million equity offering alongside an $84 million private placement with Medtronic’s subsidiary, aiming to accelerate clinical trials and scale manufacturing of its innovative DurAVR Transcatheter Heart Valve.

Osteopore Limited has partnered with DKSH Malaysia in a five-year agreement to distribute its innovative dental products, aiming to capture significant growth in Malaysia’s guided bone regeneration sector.

Clarity Pharmaceuticals has responded to ASX queries clarifying the timing and materiality of its SAR-bisFAP data presentation, denying the information was price sensitive despite a notable share price rise.